CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Marker Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Marker Therapeutics Inc
4551 KENNEDY COMMERCE DR.
Phone: (713) 400-6400p:713 400-6400 HOUSTON, TX  77032  United States Ticker: MRKRMRKR

Business Summary
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It has three multiTAA-specific T cell therapies through clinical development, including Autologous multiTAA-specific T cell therapies, Allogeneic multiTAA-specific T cell therapies and Off-the-shelf multiTAA-specific T cell therapies. It is also focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer. Autologous multiTAA-specific T cell therapies target the NY-ESO-1, PRAME, MAGE-A4, Survivin and SSX2 antigens.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
CEO PETER .HOANG
CEO PETER .HOANG
Independent Chairman of the Board N. DavidEansor 62 5/20/2022 10/17/2018
9 additional Officers and Directors records available in full report.

Business Names
Business Name
GeneMax Pharmaceuticals Canada, Inc.
GeneMax Pharmaceuticals, Inc.
Marker Cell Therapy, Inc.
5 additional Business Names available in full report.

General Information
Number of Employees: 8 (As of 12/31/2023)
Outstanding Shares: 8,902,897 (As of 3/18/2024)
Shareholders: 36
Stock Exchange: NASD
Federal Tax Id: 880277072
Fax Number: (302) 655-5049
Email Address: info@genemax.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 29, 2024